Answers are grounded in this paper and cite their sources.
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Sekeres, Mikkael A.; Santini, Valeria Membro del Collaboration Group ; Díez-Campelo, Maria; Komrokji, Rami S.; Fenaux, Pierre; Savona, Michael R.; Madanat, Yazan F.; Valcárcel-Ferreiras, David; Oliva, Esther Natalie; Regnault, Antoine; Creel, Kristin; Sengupta, Nishan; Dougherty, Souria; Shah, Sheetal; Sun, Libo; Wan, Ying; Navada, Shyamala; Zeidan, Amer M.; Platzbecker, Uwe 2024 Abstract therapy for anemic myelodyspastic patients
No takes yet. Share an insight, caveat, or question.
Sekeres et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: